



January - March 2011

Wirral DAAT

Quarter 4 2010/11

**Martin Chandler and Steven Griffith** 

DRAFT REPORT The final version will be available on the IAD website

www.cph.org.uk/iad

#### Acknowledgements:

The Authors would like to thank the NDTMS and DIP teams for their valuable support. We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts: Martin Chandler IAD Manager Centre for Public Health Faculty of Health & Applied Social Sciences Liverpool John Moores University 2nd Floor, Henry Cotton Campus, 15-21 Webster Street, Liverpool. L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith IAD Researcher

(0151) 231 4309 S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

	Р	age
Introduction		1
Arrest Referral		2
	Table 1: Individuals assessed, by Gender & Age Group	
	Table 2: Year to Date, by Gender and Age Group	
	Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Needle and Syringe	Programmes (NSPs)	4
Agenc	У	
	Table 4: Individuals by Gender	
	Table 5: Individuals by Gender: Steroid Users Omitted	
	Table 6: Individuals by Age Group	
	Table 7: Individuals by Age Group: Steroid Users Omitted	
	Table 8: Gender by Age Group of Individuals	
	Table 9: Gender by Age Group: Steroid Users Omitted	
	Table 10: Year to Date, by Gender & Age Group	
	Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted	
	Table 12: Main Drug of Use for New NSP Clients, by Gender	
	Table 13: Main Drug of Use for All NSP Clients, by Gender	
	Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, b	су
	Gender	
	Table 15: Main Drug of Use, for New NSP Clients, by Age Group	
Pharm	nacy	10
	Table 16: Individuals by Gender	
	Table 17: Main Drug of Use for All PNSP Clients, by Gender	
	Table 18: Individuals by Age Group	
	Table 19: Year to Date; by Gender & Age Group	
Combi	ined	12
	Table 20: Individuals in Agency and Pharmacy NSP, by Gender	
	Table 21: Individuals in Agency and Pharmacy NSP, by Gender: Steroid omitted	Users
	Table 22: Individuals in Agency and Pharmacy NSP, by Age Group	
	Table 23: Individuals in Agency and Pharmacy NSP, by Age Group: Ster	oid Users
	omitted	
	Table 24: Year to Date, by Gender & Age Group	
	Table 25: Combined Pharmacy and Agency NSP Total Syringes Provided	
NSP S	ervice Activity Summary	14

Table 26: All NSP transactions by NSP Type

Fig 1: NSP Service Activity; Transactions by NSP Type Table 27: NSP Transactions; Attributable Data Table 28: All NSP Individuals by NSP Type Fig 2: NSP Service Activity; Individuals by NSP Type

#### National Drug Treatment Monitoring System (NDTMS)

Table 29: Individuals in Contact with Treatment Services, by Gender
Table 30: Year to Date, by Gender
Table 31: Individuals in Contact with Treatment Services, by Age Group
Table 32: Year to Date, by Age Group
Table 33: Ethnicity of Individuals in Contact with Treatment Services
Table 34: Individuals in contact with Treatment Services, by Main Drug of Use

### Connexions

19

20

16

#### **Combined Datasets**

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group Table 36: Year to Date Problem Drug Users, by Gender & Age Group

#### **Cross Matched Datasets**

21

Fig 3: Crossover between Agency NSP and NDTMS datasets

Fig 4: Crossover between Pharmacy NSP and NDTMS datasets

Fig 5: Crossover between YTD Agency NSP and NDTMS datasets

Fig 6: Crossover between YTD Pharmacy NSP and NDTMS datasets

### Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

# **ARREST REFERRAL (AR)**

Quarter 4 (2010/11)

### Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Gender	n	%
Male	112	84.2
Female	21	15.8
Age Group		
Under 18	0	0.0
18-19	5	3.8
20-24	17	12.8
25-29	38	28.6
30-34	16	12.0
35-39	20	15.0
40-44	17	12.8
45+	20	15.0
Total	133	100

### Table 1: Individuals assessed, by Gender & Age Group

### Table 2: Year to Date, by Gender & Age Group

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	17	3.9	4	4.9	21	4.0
20-24	92	20.9	13	16.0	105	20.2
25-29	88	20.0	11	13.6	99	19.0
30-34	69	15.7	14	17.3	83	15.9
35-39	58	13.2	14	17.3	72	13.8
40-44	58	13.2	14	17.3	72	13.8
45+	58	13.2	11	13.6	69	13.2
Total	440	100	81	100	521	100

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	0	0
Benzodiazepines	1	1	0
Cannabis	15	5	0
Crack	2	7	2
Cocaine	6	12	30
Ecstasy	0	0	0
Heroin	22	11	4
Methadone	0	0	0
Other	0	0	0

### Table 3: Reported Main Drug(s)\* of Use, by Frequency of Use

#### 15 individuals did not report a main drug of use

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

## **NEEDLE AND SYRINGE PROGRAMMES**

Quarter 4 (2010/11)

### Introduction

Data are collected directly from needle and syringe programmes (NSPs). Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

### **AGENCY NSP**

### **Table 4: Individuals by Gender**

New Clients	n	%
Male	102	93.6
Female	7	6.4
Total	109	100
All Clients		
Male	463	96.3
Female	18	3.7
Total	481	100

#### Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	14	70.0
Female	6	30.0
Total	20	100
All Clients		
Male	92	86.0
Female	15	14.0
Total	107	100

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	1	0.9	2	0.4
18-19	11	10.1	21	4.4
20-24	30	27.5	116	24.1
25-29	20	18.3	89	18.5
30-34	17	15.6	69	14.3
35-39	10	9.2	69	14.3
40-44	13	11.9	58	12.1
45+	7	6.4	57	11.9
Total	109	100	481	100

## Table 6: Individuals by Age Group

# Table 7: Individuals by Age Group: Steroid Users omitted

	New C	lients	All Cl	ients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	10.0	2	1.9
20-24	2	10.0	3	2.8
25-29	3	15.0	7	6.5
30-34	1	5.0	10	9.3
35-39	3	15.0	18	16.8
40-44	5	25.0	31	29.0
45+	4	20.0	36	33.6
Total	20	100	107	100

	Gender			
	Ma	ale	Ferr	nale
Age Group	n	%	n	%
Under 18	2	0.4	0	0.0
18-19	19	4.1	2	11.1
20-24	116	25.1	0	0.0
25-29	87	18.8	2	11.1
30-34	67	14.5	2	11.1
35-39	66	14.3	3	16.7
40-44	53	11.4	5	27.8
45+	53	11.4	4	22.2
Total	463	100	18	100

# Table 8: Gender by Age Group of Individuals

## Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Ma	ale	Fen	nale
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	2	13.3
20-24	3	3.3	0	0.0
25-29	5	5.4	2	13.3
30-34	9	9.8	1	6.7
35-39	15	16.3	3	20.0
40-44	27	29.3	4	26.7
45+	33	35.9	3	20.0
Total	92	100	15	100

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	8	0.7	0	0.0	8	0.7
18-19	64	5.5	2	4.1	66	5.5
20-24	313	27.0	1	2.0	314	26.0
25-29	227	19.6	6	12.2	233	19.3
30-34	161	13.9	10	20.4	171	14.2
35-39	162	14.0	14	28.6	176	14.6
40-44	118	10.2	11	22.4	129	10.7
45+	105	9.1	5	10.2	110	9.1
Total	1,158	100	49	100	1,207	100

## Table 10: Year to Date, by Gender & Age Group

### Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

		Ger				
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	1	0.5	0	0.0	1	0.4
18-19	1	0.5	2	5.0	3	1.2
20-24	8	3.8	1	2.5	9	3.6
25-29	15	7.1	5	12.5	20	7.9
30-34	21	9.9	8	20.0	29	11.5
35-39	48	22.6	13	32.5	61	24.2
40-44	59	27.8	7	17.5	66	26.2
45+	59	27.8	4	10.0	63	25.0
Total	212	100	40	100	252	100

	Ma	ale	Female		
Drug of Use	n	%	n	%	
Amphetamines	0	0.0	0	0.0	
Melanotan	0	0.0	2	28.6	
Cocaine	0	0.0	0	0.0	
Crack	1	1.0	0	0.0	
Heroin	10	9.8	2	28.6	
Methadone	0	0.0	0	0.0	
Steroids	88	86.3	1	14.2	
Morphine	0	0.0	0	0.0	
Unknown	1	1.0	2	28.6	
Total	102	100	7	100	

## Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

## Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender				
	Ma	ale	Female		
Drug of Use	n	%	n	%	
Amphetamines	4	0.9	0	0.0	
Melanotan	3	0.6	3	16.7	
Cocaine	2	0.4	0	0.0	
Crack	1	0.2	0	0.0	
Heroin	64	13.8	5	27.8	
Methadone	15	3.2	3	16.7	
Morphine	1	0.2	0	0.0	
Steroids	371	80.1	3	16.7	
Unknown	2	0.4	4	22.2	
Total	463	100	18	100	

	Gender					
	Ma	ale	Female			
Drug of Use	n	%	n	%		
Amphetamines	6	0.5	0	0.0		
Melanotan	9	0.8	5	10.4		
Cocaine	5	0.4	1	2.1		
Crack	2	0.2	0	0.0		
Heroin	154	13.3	22	45.8		
Methadone	24	2.1	3	6.3		
Morphine	2	0.2	0	0.0		
Steroids	942	81.6	8	16.7		
Unknown	10	0.9	9	18.75		
Total	1,154	100	48	100		

### Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

### Year to Date; Melanotan Clients

• 6 clients reported using Melanotan as their primary drug this quarter

	•	heta- ine		aine/ ack		oin/ phine	Meth	adone	Ster	oids	Unkr	nown
Age Group	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5	0	0.0
18-19	0	0.0	0	0.0	0	0.0	0	0.0	19	5.1	1	16.6
20-24	0	0.0	0	0.0	0	0.0	0	0.0	113	30.2	1	16.6
25-29	0	0.0	0	0.0	4	5.7	0	0.0	82	21.9	0	0.0
30-34	1	25.0	1	33.3	7	10.0	1	5.6	59	15.8	0	0.0
35-39	0	0.0	1	33.3	14	20.0	2	11.1	51	13.6	1	16.6
40-44	1	25.0	0	0.0	27	38.6	2	11.1	27	7.2	1	16.6
45+	2	50.0	1	33.3	18	25.7	13	72.2	21	5.6	2	33.3
Total	4	100	3	100	70	100	18	100	374	100	6	100

Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

\* % Totals are by drug, not Age Group

# **PHARMACY NSPs**

## Table 16: Individuals by Gender

New Clients	n	%
Male	114	87.0
Female	17	13.0
Total	131	100
All Clients		
Male	208	87.0
Female	31	13.0
Total	239	100

### Table 17: Main Drug of Use for All PNSP Clients, by Gender

	Gender				
	Ma	ale	Female		
Drug of Use	n	%	n	%	
Crack	10	4.8	0	0.0	
Heroin	107	51.4	14	45.2	
Methadone	20	9.6	2	6.5	
Melanotan	0	0.0	1	3.2	
Steroids	4	1.9	0	0.0	
Unknown	67	32.2	14	45.2	
Total	208	100	31	100	

### Table 18: Individuals by Age Group

	New (	Clients	All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	1.5	2	< 1
20-24	11	8.4	14	5.9
25-29	12	9.2	17	7.1
30-34	27	20.6	40	16.7
35-39	23	17.6	48	20.1
40-44	39	29.8	63	26.4
45+	17	13.0	55	23.0
Total	131	100	239	100

		Ger				
	Male Female Total in Age Gro			ge Group		
Age Group	n	%	n	%	n	%
Under 18	1	< 1	1	1.3	2	< 1
18-19	1	< 1	2	2.5	3	< 1
20-24	31	6.0	4	5.1	35	5.9
25-29	45	8.7	5	6.3	50	8.4
30-34	66	12.8	18	22.8	84	14.1
35-39	105	20.3	15	19.0	120	20.2
40-44	124	24.0	14	17.7	138	23.2
45+	143	27.7	20	25.3	163	27.4
Total	516	100	79	100	595	100

## Table 19: Year to Date; by Gender & Age Group

## **COMBINED PHARMACY AND AGENCY NSP**

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

New Clients	n	%
Male	243	89.0
Female	30	11.0
Total	273	100
All Clients		
Male	714	93.2
Female	52	6.8
Total	766	100

### Table 21: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted\*

New Clients	n	%
Male	129	83.2
Female	26	16.8
Total	155	100
All Clients		
Male	305	86.9
Female	46	13.1
Total	351	100

\*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 22: Individuals in Agency and Pharmacy NSP , by Age Group

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	3	1.1	4	0.5
18-19	13	4.8	22	2.9
20-24	46	16.8	139	18.2
25-29	37	13.6	114	14.9
30-34	48	17.6	116	15.2
35-39	37	13.6	124	16.2
40-44	60	22.0	131	17.1
45+	29	10.6	115	15.0
Total	273	100	765	100

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	2.6	4	1.1
20-24	13	8.4	19	5.4
25-29	15	9.7	24	6.8
30-34	29	18.7	51	14.5
35-39	25	16.1	67	19.1
40-44	48	31.0	99	28.2
45+	21	13.5	87	24.8
Total	155	100	351	100

### Table 23: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

### Table 24: Year to Date, by Gender & Age Group

	Gender					
	Ma	ale	Fem	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	8	0.5	2	1.5	10	0.5
18-19	63	3.5	4	3.0	67	3.5
20-24	367	20.7	5	3.7	372	19.5
25-29	279	15.7	13	9.7	292	100
30-34	257	14.5	29	21.6	286	15.0
35-39	288	16.2	29	21.6	317	16.6
40-44	258	14.5	28	20.9	286	15.0
45+	257	14.5	24	17.9	281	14.7
Total	1,777	100	134	100	1,911	100

### Table 25: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	21,957	8,499	30,456	134,324

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.


# NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

### Table 26: All NSP transactions by NSP Type

All Transactions	n	%
Arch Initiatives	179	9.3
Harm Reduction Unit, St Catherine's	958	49.9
Pharmacy NSPs	783	40.8
Total	1,920	100

### Fig 1: NSP Service Activity; Transactions by NSP Type




### Table 27: NSP Transactions, Attributable Data

All Attributable Transactions	n	%*
Arch Initiatives	174	9.6
Harm Reduction Unit, St Catherine's	926	51.2
Pharmacy NSPs	707	39.2
Total	1,807	100

\*Represents proportion of transactions that were attributable during the current quarter.

All Clients	n	%
Arch Initiatives	92	11.3
Harm Reduction Unit, St Catherine's	481	59.2
Pharmacy NSPs	239	29.5
Total	812	100

# Fig 2: NSP Service Activity; Individuals by NSP Type



# National Drug Treatment Monitoring System (NDTMS) Quarter 4 (2010/11)

#### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

#### **New Clients**

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

New Clients	n	%
Male	221	73.7
Female	79	26.3
Total	300	100
All Clients		
Male	1,900	72.4
Female	726	27.6
Total	2,626	100

Table 29: Individuals in Contact with Treatment Services, by Gender

#### Table 30: Year to Date, by Gender

New Clients	n	%
Male	617	75.9
Female	196	24.1
Total	813	100
All Clients		
Male	1,982	72.5
Female	750	27.5
Total	2,732	100

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	22	7.3	118	4.5
18-19	5	1.7	45	1.7
20-24	29	9.7	224	8.5
25-29	38	12.7	422	16.1
30-34	46	15.3	510	19.4
35-39	61	20.3	598	22.8
40-44	54	18.0	410	15.6
45+	45	15.0	299	11.4
Total	300	100	2,626	100

## Table 31: Individuals in Contact with Treatment Services, by Age Group

Table 32: Year to Date, Individuals in Contact with Treatment Services, by Age Group

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	66	8.1	131	4.8
18-19	23	2.8	46	1.7
20-24	90	11.1	232	8.5
25-29	105	12.9	428	15.7
30-34	146	18.0	531	19.4
35-39	137	16.9	623	22.8
40-44	122	15.0	429	15.7
45+	124	15.3	312	11.4
Total	813	100	2,732	100

	New Clients		All Clients	
Ethnicity	n	%	n	%
White British	285	95.0	2,569	97.8
White Irish	2	< 1	11	< 1
Other White	0	0.0	4	< 1
White & Black Caribbean	2	< 1	6	< 1
White and Black African	0	0.0	1	< 1
Other Black	4	1.4	9	< 1
White & Asian	0	0.0	3	< 1
Other Asian	0	0.0	2	< 1
Other Mixed	1	< 1	7	< 1
Caribbean	1	< 1	2	< 1
Chinese	0	0.0	0	0.0
Other	0	0.0	4	< 1
Unknown	5	1.7	8	< 1
Total	300	100	2,626	100

### Table 33: Ethnicity of Individuals in Contact with Treatment Services

## Table 34: Individuals in Contact with Treatment Services, by Main Drug of Use

	New Clients		All Clients	
Drug of Use	n	%	n	%
Heroin	122	40.7	1,788	68.1
Methadone	33	11.0	178	6.8
Other Opiates	20	6.7	68	2.6
Benzodiazepines	0	0.0	7	< 1
Amphetamines	5	1.7	47	1.8
Cocaine	39	13.0	197	7.5
Crack	18	6.0	72	2.7
Hallucinogens	0	0.0	1	< 1
Ecstasy	1	< 1	3	< 1
Cannabis	56	18.7	229	8.7
Antidepressants	0	0.0	1	< 1
Prescription Drugs	5	1.7	19	< 1
Mephedrone	1	< 1	3	< 1
Other/Unknown	0	0.0	13	< 1
Total	300	100	2,626	100

# CONNEXIONS

Quarter 4 (2010/11)

Due to recent changes in Data Sharing Protocols we were not able to access Connexions data in time for this report.

### **COMBINED DATASETS**

#### Quarter 4 (2010/11)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Gender	n	%
Male	2,446	76.4
Female	757 23.6	
Age Group		
Under 18	121	3.8
18-19	68	2.1
20-24	347	10.8
25-29	513	16.0
30-34	588	18.4
35-39	678	21.2
40-44	503	15.7
45+	385	12.0
Total	3,203	100

### Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

#### Table 36: Year to Date, by Gender and Age Group

	Gender					
	Male		Female		Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	108	3.0	29	3.4	137	3.1
18-19	99	2.7	27	3.1	126	2.8
20-24	553	15.3	81	9.4	634	14.2
25-29	554	15.4	141	16.4	695	15.6
30-34	589	16.3	168	19.6	757	16.9
35-39	664	18.4	186	21.7	850	19.0
40-44	550	15.2	132	15.4	682	15.3
45+	491	13.6	95	11.1	586	13.1
Total	3,608	100	859	100	4,467	100


# **CROSS-MATCHED DATASETS**

### Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.


For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.



### Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets

#### Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets








Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

